{"count": 1, "results": [{"_id": "36145361", "pmid": 36145361, "pmcid": "PMC9505840", "title": "Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4", "journal": "Pharmaceuticals (Basel)", "authors": ["Yang A", "Lau ESH", "Wu H", "Ma RCW", "Kong APS", "So WY", "Luk AOY", "Fu AWC", "Chan JCN", "Chow E"], "date": "2022-09-13T00:00:00Z", "doi": "10.3390/ph15091140", "meta_date_publication": "2022 Sep 13", "meta_volume": "15", "meta_issue": "9", "meta_pages": "", "score": 50264.594, "text_hl": "These real-world data underscore the @<m>DISEASE_Epilepsy_Tonic_Clonic</m> @DISEASE_MESH:D004830 @@@major@@@ benefits and low risk of @DISEASE_Acidosis_Lactic @DISEASE_MESH:D000140 @@@lactic acidosis@@@ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use down to an eGFR of 30 mL/min/1.73 m2 and possibly even 15 mL/min/1.73 m2, while reinforcing the importance of dose adjustment and frequent monitoring of eGFR.", "citations": {"NLM": "Yang A, Lau ESH, Wu H, Ma RCW, Kong APS, So WY, Luk AOY, Fu AWC, Chan JCN, Chow E. Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4 Pharmaceuticals (Basel). 2022 Sep 13;15(9):. PMID: 36145361", "BibTeX": "@article{36145361, title={Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4}, author={Yang A and Lau ESH and Wu H and Ma RCW and Kong APS and So WY and Luk AOY and Fu AWC and Chan JCN and Chow E}, journal={Pharmaceuticals (Basel)}, volume={15}, number={9}}"}}]}